Investigational drug · Phase 3
JNT-517
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Phenylketonuria (PKU), Phenylketonuria.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
7
Any phase or sponsor naming "JNT-517"
First trial start
2022
Oct 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNT-517", any sponsor or status.
Conditions studied
As listed on its trial records.
- Phenylketonuria (PKU)
- Phenylketonuria
Approved drugs for the same conditions: Phenylketonuria (PKU) · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "JNT-517" as an intervention, largest first.
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06628128 · 240 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 1, 2027
Drug: JNT-517 · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 12 sites in all
- First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05781399 · 163 participants · Start Oct 31, 2022 · Primary completion Jul 29, 2025
Drug: JNT-517 Suspension; Placebo Suspension and 2 more · For: Phenylketonuria
Sites: Gainesville, Florida; Tampa, Florida; Atlanta, Georgia · 15 sites in all
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06971731 · 120 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 1, 2028
Drug: JNT-517; JNT-517 Matching Placebo · For: Phenylketonuria
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 26 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07446400 · 48 participants (planned) · Start Mar 31, 2026 · Primary completion Nov 7, 2026
Drug: Repinatrabit; EE/NE and 4 more · For: Healthy Volunteers
Sites: Melbourne, Australia
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07713758 · 32 participants (planned) · Start Jul 17, 2026 · Primary completion Feb 9, 2027
Drug: Repinatrabit · For: Phenylketonuria
Sites: Miami, Florida
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06637514 · 14 participants · Start Jul 16, 2025 · Primary completion May 8, 2026
Drug: JNT-517 Tablet; JNT-517 Tablet · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 7 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07573449 · 8 participants · Start Jan 22, 2024 · Primary completion Jan 22, 2025
Drug: [14C]-JNT-517 · For: Healthy Volunteers
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Engineering and immobilization of imine reductase enable chemoenzymatic synthesis of SLC6A19 inhibitor JNT-517.
Ren M, Zhang L, Song J, et al. · Bioresour Technol 2026
- SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.
Wobst HJ, Viader A, Muncipinto G, et al. · JCI Insight 2024
Also in development for Phenylketonuria (PKU)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Otsuka.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.